CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 10 enrolled
Drug / intervention
Siltuximabdrug
Likely dose
Siltuximab 11 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02641522
NCT02641522Early Ph 1Completed
CompareCT.gov

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

Carla Greenbaum, MD·interventional·Posted Dec 29, 2015·Updated Nov 2, 2018

In Brief

A Early Phase 1 clinical trial evaluating Siltuximab for Type 1 Diabetes. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsJanssen Research & Development, LLC

Timeline

Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 29, 2015
Enrollment StartMar 8, 2016
Primary CompletionMar 16, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.5 years ago

Interventions

Siltuximabdrug

Single infusion of siltuximab (11 mg/kg)